Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)
Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)
Prospective, multicenter, single arm clinical trial designed to evaluate the safety of the
 Rezūm System in treating subjects with symptomatic BPH for prostate sizes >80cm3 and ≤150
 cm3.
A prospective, multicenter, single arm clinical trial designed to evaluate the safety of the
 Rezūm System in treating subjects with symptomatic BPH for prostate sizes >80cm3 and ≤150
 cm3.
Inclusion Criteria:

 1. Male subjects ≥ 50 years of age who have symptomatic BPH.

 2. International Prostate Symptom Score (IPSS) score ≥ 13.

 3. Peak urinary flow rate (Qmax): ≥ 5ml/sec to ≤ 12 ml/sec with minimum voided volume of
 ≥ 125 ml.

 4. Post-void residual (PVR) ≤300 ml.

 5. Prostate volume >80 cm3 to ≤150 cm3

 Exclusion Criteria:

 Urology:

 1. Any prior invasive prostate intervention (e.g., "Radiofrequency" thermotherapy,
 balloon, microwave thermotherapy, "Prostatic Urethral Lift", "Transurethral
 Resection", or laser) or other surgical interventions of the prostate.

 2. Undergone a prostate biopsy within 60 days prior to the scheduled treatment date or
 has an imminent need for surgery.

 3. Verified acute bacterial prostatitis within last 12 months documented by culture.

 4. Active or history of epididymitis within the past 3 months.

 5. Urethral strictures, bladder neck contracture, unusual anatomy or muscle spasms that
 would prevent the introduction and use of the Rezūm device.

 6. Diagnosed bladder, urethral or ureteral stones or active stone passage in the past 6
 months, provided that stones that are known to be in the kidney and have been stable
 for a period exceeding 3 months are permissible.

 7. Subject interested in maintaining fertility.

 8. Use of the following medications where the dose is not stable (stable dose defined as
 the same medication and dose in the last three months):

 1. Beta-blockers;

 2. Anticonvulsants;

 3. Antispasmodics;

 4. Antihistamines;

 5. Alpha blockers for BPH and anticholinergics or cholinergics;

 6. Type II, 5-alpha reductase inhibitor (e.g., finasteride (Proscar, Propecia));

 7. Dual 5-alpha reductase inhibitor (e.g., dutasteride (Avodart));

 8. Estrogen, drug-producing androgen suppression, or anabolic steroids;

 9. PD5 Inhibitors (e.g., Viagra, Levitra or Cialis)

 9. Subjects who have had an incidence of spontaneous urinary retention either treated
 with indwelling transurethral catheter or suprapubic catheter 6 months prior to
 baseline. A provoked episode now resolved is still admissible

 10. Evidence of atonic neurogenic bladder evaluated by a baseline urodynamic assessment.

 11. Visible hematuria with subject urine sample without a known contributing factor.

 12. Presence of a penile implant or stent(s) in the urethra or prostate

 13. Active urinary tract infection by culture within 7 days of treatment or two documented
 independent urinary tract infections of any type in the past 6 months.

 Gastroenterology:

 14. Previous pelvic irradiation or radical pelvic surgery.

 15. Previous rectal surgery (other than hemorrhoidectomy) or known history of rectal
 disease.

 Nephrology:

 16. Compromised renal function defined as serum creatinine > 2.0 mg/dl.

 17. Hydronephrosis (Grade 2 or higher).

 Oncology:

 18. Prostate cancer testing:

 If PSA is > 2.5 ng/ml and ≤ 10 ng/ml with free PSA <25%, prostate cancer for the
 subject must be/had been ruled out through a negative biopsy prior to enrollment

 -  Males 50-59 years - PSA is >2.5 ng/ml and ≤10 ng/ml with free PSA <25%,

 -  Males 60+ years - PSA is >4 ng/ml and ≤10 ng/ml, with free PSA <25%

 19. History of confirmed malignancy or cancer of the prostate or bladder; however, high
 grade prostatic intraepithelial "PIN" is acceptable.

 20. History of cancer in non-genitourinary system that is not considered cured (except
 basal cell or squamous cell carcinoma of the skin). A potential participant is
 considered cured if there has been no evidence of cancer within five years of
 enrollment.

 Cardiology:

 21. History of clinically significant congestive heart failure (i.e., NYHA Class III and
 IV).

 22. Cardiac arrhythmias that are not controlled by medication and/or medical device.

 23. An episode of unstable angina pectoris, a myocardial infarction, transient ischemic
 attack, or a cerebrovascular accident within the past six months.

 Pulmonology:

 24. History of significant respiratory disease where hospitalization for the disease is
 required.

 Hematology:

 25. Diagnosed or suspected bleeding disorder, or coagulopathies.

 26. Use of antiplatelet or anticoagulant medication except low dose aspirin (<100mg/day)
 within 10 days prior to treatment.

 Endocrinology:

 27. History of diabetes not controlled by a stable dose of medication over the past three
 months, provided that patients with a hemoglobin A1c <8.0% are allowed.

 Immunology:

 28. History of immunosuppressive conditions (e.g., AIDS, post-transplant).

 Neurology:

 29. Any cognitive or psychiatric condition that interferes with or precludes direct and
 accurate communication with the study investigator regarding the study or affect the
 ability to complete the study quality of life questionnaires.

 30. Diagnosed or suspected primary neurologic conditions such as multiple sclerosis or
 Parkinson's disease or other neurological diseases known to affect bladder function,
 sphincter function or poor detrusor muscle function (< 25% of accepted and established
 nomograms).

 General:

 31. Currently enrolled in any other pre-approval investigational study in the US (does not
 apply to long-term post-market studies unless these studies might clinically interfere
 with the current study endpoints (e.g., limit use of study-required medication, etc.).

 32. Any significant medical history that would pose an unreasonable risk or make the
 subject unsuitable for the study.

 33. Inability to provide a legally effective "Informed Consent Form" and/or comply with
 all the required follow-up requirements.